Login / Signup
Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
Donald C Moore
Katelynn Granger
Hailey Hill
Allison Karabinos
James A Davis
Published in:
Expert review of hematology (2024)
Keyphrases
</>
multiple myeloma
acute lymphoblastic leukemia
hodgkin lymphoma